Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women
Completed
- Conditions
- Postmenopause
- Registration Number
- NCT00484107
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This post-marketing study will provide local safety and tolerance data on the use of Premarin® vaginal cream.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
- Patients in whom Premarin vaginal cream is indicated.
- In the opinion of the investigator, sufficient intelligence and motivation for the patient to continue throughout the study.
- Provide signed informed consent.
Exclusion Criteria
- Patients not willing to give informed consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Premarin Vaginal Cream's effects on estrogen receptor subtypes in postmenopausal vulvovaginal atrophy?
How does Premarin Vaginal Cream compare to estradiol-based therapies in managing postmenopausal symptoms in South Asian populations?
Which biomarkers correlate with adverse event risk in Indian postmenopausal women using conjugated estrogens vaginal formulations?
What are the long-term safety profiles of Premarin Vaginal Cream versus systemic HRT in postmenopausal women with estrogen receptor α polymorphisms?
How do combination therapies of Premarin Vaginal Cream with non-estrogen alternatives like ospemifene impact local tissue health in postmenopausal Indian patients?